8:01 AM ET
8-K
Investor Presentation
60 Degrees Pharmaceuticals Investor Presentation
60 Degrees Pharmaceuticals updated its investor presentation for use in meetings with investors and analysts, specifically highlighting progress for Tafenoquine in treating Babesiosis. The presentation was featured at the 2026 ILADS Annual Scientific Conference and outlines a regulatory objective for a potential sNDA submission in 2027.